## Title: Comparing the test performance of dried-blood-spot and plasma HIV 1 2 recent infection testing samples in a nationally scaled sex worker programme in Zimbabwe 3 Authorship: Brian D Rice<sup>1</sup>, Harriet S Jones<sup>2</sup>, Fortunate Machingura<sup>3</sup>, Leah Gaihai<sup>3</sup>, Memory 4 Makamba<sup>3</sup>, Thomas Chanyowedza<sup>3</sup>, Panganai Masvikeni<sup>3</sup>, Edward Matsikire<sup>3</sup>, Primrose 5 6 Matambanadzo<sup>3</sup>, Sithembile Musemburi<sup>3</sup>, Phillip N Chida<sup>3</sup>, Jeffery Dirawo<sup>3</sup>, Owen Mugurungi<sup>4</sup>, 7 Sarah Bourdin<sup>2</sup>, James R Hargreaves<sup>2</sup>, Gary Murphy<sup>5</sup>, Frances M Cowan<sup>3,6</sup> **Affiliations:** 8 1. University of Sheffield, School of Medicine and Population Health, Sheffield, United Kingdom 9 2. London School of Hygiene and Tropical Medicine, Faculty of Public Health and Policy, 10 11 London, United Kingdom 12 3. Centre for Sexual Health and HIV/AIDS Research (CeSHHAR) Zimbabwe, Harare, 13 Zimbabwe 4. AIDS and TB Directorate, Ministry of Health and Child Care, Harare, Zimbabwe 14 15 5. Independent consultant, London, United Kingdom 16 6. Liverpool School of Tropical Medicine, Faculty of Global Health, Liverpool, United Kingdom 17 Abstract 18 Recency testing can provide strategic insights as to whether a person newly diagnosed with HIV 19 recently acquired their infection or not. To understand potential biases associated with HIV 20 recency testing, we explored the extent sample type influences whether a person is assigned as 21 being recent. Implementing a laboratory-based Recent Infection Testing Algorithm (RITA) across 22 the Centre for Sexual Health and HIV/AIDS Research (CeSHHAR) key populations programme in Zimbabwe between October 2021 and January 2023, we compared plasma-based and dried-23 bloodspot (DBS) HIV recency samples. Over the study period, 24,976 individual female sex 24

25 workers HIV tested, of whom 9.5% (2,363/24,979) newly tested HIV positive. Of these 2,363 26 women, 55.5% (1311/2,363) were offered and gave consent for a sample to be taken for DBS recency and viral load testing, among whom 11.7% (153/1,311) were classified as having a recent 27 28 infection. A subset of 464 women were offered and consented to paired sample collection, among 29 whom 10.1% (47) and 12.3% (57) of plasma and DBS samples, respectively, were classified as 30 recent. Overall, categorical determination was good, with 97% of results concordant. Of 58 women 31 with paired sample collection who had a test result classified as recent, 46 (79.3%) were concordant 32 recent on both DBS and plasma, with 12 (20.7%) being dis-concordant. Of these 12 women's samples, 11 were deemed long-standing by the plasma assay but recent by the paired DBS, and 33 34 one deemed long-standing by DBS but recent by the paired plasma sample. Depending on use-35 case and setting, there are trade-offs when considering DBS or plasma-based samples between test 36 performance and ease of implementation. Our data can help inform statistical adjustments to 37 harmonise cut-offs on DBS and plasma assays, thereby improving the use and interpretation of 38 recency assays in population-level HIV surveillance activities.

## 39 Introduction

If we are to achieve sustainable HIV epidemic control, we need to better understand epidemic 40 41 dynamics and improve the efficiency of programme service delivery. In gaining strategic insights of patterns and distributions of new HIV infections, and in prioritising prevention and testing 42 43 interventions, there has been much discussion about the use of recency testing in programmatic 44 setting [1-6]. Recency testing can help identify whether a person newly diagnosed with HIV recently acquired their infection (usually <one year) or not [1]. As a disproportionate number of 45 HIV transmissions originate from people who have early HIV infection [7], identifying people or 46 populations with recent infections has strategic potential to inform where interventions should be 47 prioritised to reduce overall levels of transmission. 48

In relation to epidemic dynamics, it has been argued that there is a clear rationale for the use of recency assays for population-level HIV incidence estimation [2]. However, in relation to helping programmes focus limited resources to populations with the greatest potential benefit, it has been contended that their application for non-incidence use cases remains questionable [2].

In previous research we have shown the pragmatic application of laboratory-based HIV recency testing in programme settings in Kenya and Zimbabwe to be feasible [3,4]. Among calls for further research to better understand the potential biases associated with HIV recency testing [1,2,5,6], has been a request to explore the extent sample type influences whether a person is assigned as being recent [8]. In the context of a national scaled sex worker programme in Zimbabwe we explored whether conducting plasma-based HIV recency testing, in addition to our standard approach using DBS, impacted on recent HIV infection classification.

### 60 Methods

We implemented a laboratory-based Recent Infection Testing Algorithm (RITA) across the Centre
for Sexual Health and HIV/AIDS Research (CeSHHAR) key populations programme (formerly
known as the Sisters with a Voice programme) in Zimbabwe between October 2021 and January
2023. The programme has been described elsewhere [9]. Since the programme's initiation in 2009,
HIV testing coverage has increased substantially and those attending services are likely to be
representative of female sex workers (FSW) in Zimbabwe [10-12].

All FSW testing newly HIV positive during the study period were eligible for enrolment in the study if aged 18 years and older and having received a confirmatory HIV positive test result, in line with Zimbabwe's national testing algorithm. Those under 18 years, with an indeterminate HIV test result or prior history of testing HIV-positive, or reported as being in receipt of anti-retroviral therapy, were excluded from enrolment. Informed consent was sought from all eligible women. A DBS sample was collected for each consenting woman, with samples tested using the Maxim HIV-1 Limiting Antigen Avidity (LAg Avidity) Enzyme Immunoassay (EIA) in accordance with the

product insert (DBS KIT CAT NO. 92003) [13]. Samples were stored at clinic sites at room
temperature in gas impermeable plastic bags with desiccant sachets to keep them dry. Samples
were collected from sites every 14 days by a designated study driver and delivered to the Flow
Cytometry Laboratory in Harare.

Ethylenediaminetetraacetic Acid (EDTA) whole blood samples were also collected from a sub-set of consenting women at pre-identified Sisters clinics with the capacity for samples to reach the laboratory within 24 hours. Sites collecting plasma samples stored these in cool boxes with thermometers and trackers to monitor the temperature and timely delivery to the lab. Cooler boxes were collected at the end of each day by a delivery company. At the laboratory, EDTA whole blood samples were checked using quality control procedures and stored at 20 degrees Celsius.

Samples with a normalised optical density (ODn) <2.0 underwent retesting in triplicate from a</li>
fresh dilution of the specimen to confirm the HIV LAg result. Samples with a final ODn >1.5
after retesting were classified as long-term HIV infection. Viral load testing was performed with
a NucliSens assay on anti-HIV-1 positive samples with a final ODn ≤1.5. Samples with an ODn
≤1.5 and a viral load <1000 copies/ml denoted long-term infection, and those with an ODn ≤1.5</li>
and a viral load ≥1000 copies/ml were classified as recent infection. Those samples with an ODn
of <0.4 were retested with an HIV-1 ELISA test to confirm they were HIV-1 seropositive.</li>

#### 91 Results

92 Over the study period, 24,976 individual FSW HIV tested at CeSHHAR programme clinics, of 93 whom 9.5% (2,363/24,979) newly tested HIV positive. Of these 2,363 women, 55.5% 94 (1311/2,363) were offered and gave consent for a sample to be taken for DBS recency and viral 95 load testing and were enrolled in the study. Among these women no samples were rejected, and 96 11.7% (153/1,311) were classified as having a recent infection.

97 Focusing on pre-identified clinics capable of plasma testing and transport, 464 women were98 offered and consented to paired sample collection (i.e. DBS and plasma, and viral load). Among

99 these 464 women, plasma testing classified 10.1% (47) as having a recent infection, with DBS 100 classifying 12.3% (57) (table 1). Of the 58 women with paired sample collection who had a test 101 result classified as recent, 46 (79.3%) were concordant recent on both DBS and plasma, with 12 102 (20.7%) being dis-concordant. Eleven samples were deemed long-standing by the plasma assay but 103 recent by the paired DBS, and one deemed long-standing by DBS but recent by the paired plasma 104 sample. Overall, there was 97.4% (452/464) concordance between the DBS and plasma samples.

		DBS		
		Long-term	Recent	Total
	Long-term	406	11	417
Plasma	Recent	1	46	47
	Total	407	57	464

105 Table 1: RITA classification of plasma and DBS samples

Figure 1 compares ODn values of plasma and DBS samples. Of the 12 samples that were not in agreement for recent infection classification (pink dots), 3 had very different ODn values. The remaining 9 fell close to either side of the 1.5ODn cut-off. Figure 2 shows that, on average, plasma samples had higher ODn by a mean difference of 0.53 ODn (SD 0.98). Tests however did not show consistent variance across the range of ODn values, with ODn agreement being better at values below 2.

## 112 Figure 1: ODn values for plasma and DBS samples

113

## 114 Figure 2: Bland-Altman plot of plasma and DBS ODn on paired samples

- 115
- 116 Discussion

117 To gain additional insights into routine HIV recent infection testing within a national scaled sex

118 worker programme in Zimbabwe, we compared results using DBS and plasma samples. Overall,

categorical determination was good, with 97% of results concordant. However, we found the use of different sample types impacted on recent HIV infection classification. On average, plasma samples had a higher ODn than DBS samples, with a mean difference of 0.53. This difference resulted in a higher percentage of women being classified as recent positive on their DBS sample versus plasma (12.2% versus 10.3%).

In a previous study test matching 100 plasma and DBS samples, DBS samples were more likely to 124 be classified as recent [8]. The study's authors suggested DBS protocols could be adjusted to 125 126 account for false recency results, or that appropriate changes to assay cut-offs could be applied to 127 account for the higher rate of recency positive test results arising from DBS. In relation to false recency results, we were unable to explore this in our study beyond including a viral load in our 128 129 RITA. However, we can assume that both the plasma and DBS recent classified results are likely 130 to include misclassification. We previously reported in Siaya county in Western Kenya that of eleven women classified as recent based on their LAg plasma samples and viral-load tests, one was 131 reclassified as long-standing after a review of clinical documentation that showed she had initiated 132 HIV treatment almost four years prior (recency misclassification of 9.1%) [3]. In Nairobi, Kenya, 133 we previously reported that of 48 people testing recent based on their DBS sample and viral load 134 one woman and one man were reclassified following antiretroviral therapy metabolite testing 135 (misclassification of 4.2%) [3]. In relation to applying assay cut-offs, our data (preferably in 136 137 combination with other complementary data) could be utilised to inform a statistical adjustment 138 to harmonise cut-offs on DBS and plasma samples.

When conducting recency testing using DBS or plasma for different use-cases [2], there are factors in addition to test accuracy to be considered, for example implementation. In relation to three pilot studies of HIV recency testing we previously conducted in Kenya and Zimbabwe, we reported testing acceptance rates to differ by sample type (higher acceptance rates for DBS than plasma) [3,4]. We also reported how DBS sample collection was simpler than plasma sampling, as

144 they could be transported and stored dry at room temperature (plasma requires maintenance of a cold chain during transportation and storage) [4]. In implementing the collection of both sample 145 types, it was our experience in this study that DBS samples were easier to collect, transport and 146 147 store than plasma samples. However, we also found DBS samples to be less timely than plasma due to the need for elution before testing. The issue of timeliness, however, was somewhat negated 148 149 by the necessity for all recency tests to be analysed alongside viral load results for validation. This need for additional information, such as viral load, to interpret results, and to confirm HIV 150 151 diagnosis, also equalises potential time gains from adopting recency point-of-care tests over laboratory-based testing for incidence estimation. We should note that concerns relating to low 152 sensitivity for the detection of recent infection have also been raised in relation to point-of-care 153 154 tests [14,15].

Laboratory-based recency testing, when conducted optimally, can distinguish recently acquired infection from long-standing infection among persons newly diagnosed with HIV. Depending on use-case and setting, however, there are trade-offs when considering DBS or plasma-based samples between test performance and ease of implementation. In comparing DBS and plasma test results, we present information that can improve the use and interpretation of recency assays in population-level HIV surveillance activities.

#### 161 Acknowledgments


We thank the women who enrolled in our study and those who visited CeSHHAR's Key
Populations programme during the study period, all contributing data to this analysis. We thank
everyone who has dedicated time to implementing CeSHHAR's Key Populations programme.

### 165 References


166	1.	Joint United Nations Programme on	HIV	/AIDS and the World Health (	Dreanization. Using

- 167 Recency Assays for HIV Surveillance 2022 technical guidance. Final report. Geneva: Joint
- 168 United Nations Programme on HIV/AIDS and the World Health Organization; 2022.
- 169 2. Facente SN, Grebe E, Maher AD, Fox D, Scheer S, Mahy M, et al. Use of HIV Recency
- 170 Assays for HIV Incidence Estimation and Other Surveillance Use Cases: Systematic Review.
- 171 JMIR Public Health Surveill. 2022;8(3):e34410.
- 172 3. Rice BD, de Wit M, Welty S, Risher K, Cowan FM, Murphy G, et al. Can HIV recent
- infection surveillance help us better understand where primary prevention efforts should be
- targeted? Results of three pilots integrating a recent infection testing algorithm into routine
- 175 programme activities in Kenya and Zimbabwe. J Int AIDS Soc. 2020;23 Suppl 3(Suppl
- **176** 3):e25513.
- 177 4. de Wit MM, Rice B, Risher K, Welty S, Waruiru W, Magutshwa S, et al. Experiences and
- 178 lessons learned from the real-world implementation of an HIV recent infection testing
- 179 algorithm in three routine service-delivery settings in Kenya and Zimbabwe. BMC Health
- 180 Serv Res. 2021;21(1):596.
- 181 5. World Health Organization. Consolidated guidelines on person-centred HIV strategic
- information: strengthening routine data for impact. Final report. Geneva: World HealthOrganization; 2022.
- 184 6. amfAR. Blinded by Our Own Data Recency Testing in PEPFAR. Washington DC: amfAR;
- 185 2022. Available from <u>https://www.amfar.org/wp-</u>
- 186 <u>content/uploads/2022/05/amfar\_recency\_report\_20220531.pdf</u>
- 187 7. Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, et al. Brief but efficient:
- acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189(10):1785-92.

189	8.	Schlusser KE, Pilcher C, Kallas EG, Santos BR, Deeks SG, Facente S, et al. Comparison of
190		cross-sectional HIV incidence assay results from dried blood spots and plasma. PLoS One.
191		2017;12(2):e0172283.
192	9.	Cowan FM, Chabata ST, Musemburi S, Fearon E, Davey C, Ndori-Mharadze T, et al.
193		Strengthening the scale-up and uptake of effective interventions for sex workers for
194		population impact in Zimbabwe. J Int AIDS Soc. 2019;22 Suppl 4(Suppl 4):e25320.
195	10	. Cowan FM, Davey CB, Fearon E, Mushati P, Dirawo J, Cambiano V, et al. The HIV Care
196		Cascade Among Female Sex Workers in Zimbabwe: Results of a Population-Based Survey
197		From the Sisters Antiretroviral Therapy Programme for Prevention of HIV, an Integrated
198		Response (SAPPH-IRe) Trial. J Acquir Immune Defic Syndr. 2017;74:375-82.
199	11.	. Chabata ST, Fearon E, Webb EL, Weiss HA, Hargreaves JR, Cowan FM. Assessing Bias in
200		Population Size Estimates Among Hidden Populations When Using the Service Multiplier
201		Method Combined With Respondent-Driven Sampling Surveys: Survey Study. JMIR Public
202		Health Surveill. 2020;6: e15044.
203	12	. Jones HS, Hensen B, Musemburi S, Chinyanganya L, Takaruza A, Chabata ST, et al.
204		Interpreting declines in HIV test positivity: an analysis of routine data from Zimbabwe's
205		national sex work programme, 2009-2019. J Int AIDS Soc. 2022;25(7):e25943.
206	13	. MaximBio. Maxim HIV-1 Limiting Antigen Avidity EIA. Rockville, MD: 2024. Available
207		from https://maximbio.com/covid-hiv-test-kit/hiv-1-limiting-antigen-eia/
208	14	. Galiwango RM, Ssuuna C, Kaleebu P, Kigozi G, Kagaayi J, Nakigozi G, et al. Validation of
209		the Asante HIV-1 Rapid Recency Assay for Detection of Recent HIV-1 Infections in
210		Uganda. AIDS Res Hum Retroviruses. 2021;37(12):893-896.
211	15	. Singh B, Mthombeni J, Olorunfemi G, Goosen M, Cutler E, Julius H, et al. Evaluation of the
212		accuracy of the Asanté assay as a point-of-care rapid test for HIV-1 recent infections using
213		serum bank specimens from blood donors in South Africa, July 2018 - August 2021. S Afr
214		Med J. 2023;113(10):42-48.



# Figure



# Figure